Средната преживяемост е била съответно 7, 34 и 5, 66 месеца за TMZ и прокарбазин (log- rank p = 0, 33).
At 6 months, the fraction of surviving patients was significantly higher in the TMZ arm (60%) compared with the procarbazine arm (44%) (chi-square p = 0.019).